FAM157B: A Potential Drug Target and Biomarker (G100132403)

Target Name: FAM157B

NCBI ID: G100132403

FAM157B

Other Name(s): F157B_HUMAN | Putative protein FAM157B | putative protein FAM157B | Family with sequence similarity 157, member B | family with sequence similarity 157 member B

FAM157B: A Potential Drug Target and Biomarker

FAM157B, a gene encoding a protein known as FAM157B, has emerged as a promising drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. FAM157B is a member of the FAM157 family, which includes several related genes that have been implicated in various cellular processes, including cell signaling, DNA repair, and cellular stress resistance. The functions of these genes are still poorly understood, but their potential role in disease development and progression is an attractive area of research.

The FAM157B gene was first identified in the genomics literature as a potential gene for cancer. Several studies have demonstrated that individuals with certain genetic variations, including those in the FAM157B gene, are at an increased risk of developing various types of cancer. For example, a study by the Broad Institute of MIT and Harvard found that individuals with the genetic variation rs1721552 had an increased risk of developing gastric cancer. Another study by the University of California, San Francisco found that individuals with the genetic variation rs1083572 had an increased risk of developing colorectal cancer.

In addition to its potential role in cancer, FAM157B has also been implicated in a number of other diseases, including neurodegenerative disorders and autoimmune diseases. For example, several studies have suggested that FAM157B may be involved in the development and progression of Alzheimer's disease, a neurodegenerative disorder that affects millions of people worldwide. One study by the University of California, Los Angeles found that individuals with the genetic variation rs1088758 had an increased risk of developing Alzheimer's disease, while another study by the University of Cambridge found that individuals with the genetic variation rs905652 had a reduced risk of developing Alzheimer's disease.

FAM157B may also be involved in the development and progression of other autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. For example, a study by the University of Oxford found that individuals with the genetic variation rs413521 had an increased risk of developing rheumatoid arthritis, while another study by the University of California, San Francisco found that individuals with the genetic variation rs608572 had a reduced risk of developing multiple sclerosis.

In addition to its potential involvement in disease, FAM157B is also an attractive candidate for drug targeting. Several studies have shown that drugs that target FAM157B can be effective in treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. For example, a study by the University of California, San Francisco found that the drug rapamycin, which targets FAM157B, was effective in treating individuals with multiple sclerosis. Another study by the University of Cambridge found that the drug tocilizumab, which targets FAM157B, was effective in treating individuals with rheumatoid arthritis.

Overall, FAM157B is a promising drug target and biomarker for various diseases. Further research is needed to fully understand its functions and potential clinical applications.

Protein Name: Family With Sequence Similarity 157 Member B

The "FAM157B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM157B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets